Citations

Clear

3942 citation(s) found for "To, Van".

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
Gralow, Julie R. , Barlow, William E. , Paterson, Alexander , Lew, Danika L., Stopeck, Alison , Hayes, Daniel F. , Hershman, Dawn L. , Schubert, Mark M., Clemons, Mark , Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Dammann, Kim Z, Abrams, Jeffrey S. , Livingston, Robert B., Ingle, James N. , Hershman, Dawn L , Gralow, Julie R , Barlow, William E , Miao, Jieling , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 28, 2019 | Volume: 112 | Issue: 7 | Pages: 698-707

10.1093/jnci/djz215 | PMID 31693129 Get It

Abstract Background Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates in postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Oncology study S0307 compared the efficacy of three bisphosphonates in early-stage breast cancer. Methods Patients with stage I–III breast cancer were randomly assigned to 3 years of intravenous zoledronic acid, oral clodronate, or oral ibandronate. The primary endpoint was disease-free survival (DFS) with overall survival as a secondary outcome. All statistical tests were two-sided. Results A total of 6097 patients enrolled. Median age was 52.7 years. Prior to being randomly assigned, 73.2% patients indicated preference for oral vs intravenous formulation. DFS did not differ across arms in a log-rank test (P = .49); 5-year DFS was 88.3% (zoledronic acid: 95% confidence interval [CI] = 86.9% to 89.6%), 87.6% (clodronate: 95% CI = 86.1% to 88.9%), and 87.4% (ibandronate: 95% CI = 85.6% to 88.9%). Additionally, 5-year overall survival did not differ between arms (log rank P = .50) and was 92.6% (zoledronic acid: 95% CI = 91.4% to 93.6%), 92.4% (clodronate: 95% CI = 91.2% to 93.5%), and 92.9% (ibandronate: 95% CI = 91.5% to 94.1%). Bone as first site of recurrence did not differ between arms (P = .93). Analyses based on age and tumor subtypes showed no treatment differences. Grade 3/4 toxicity was 8.8% (zoledronic acid), 8.3% (clodronate), and 10.5% (ibandronate). Osteonecrosis of the jaw was highest for zoledronic acid (1.26%) compared with clodronate (0.36%) and ibandronate (0.77%). Conclusions We found no evidence of differences in efficacy by type of bisphosphonate, either in overall analysis or subgroups. Despite an increased rate of osteonecrosis of the jaw with zoledronic acid, overall toxicity grade differed little across arms. Given that patients expressed preference for oral formulation, efforts to make oral agents available in the United States should be considered.
Infographic. Can even experienced orthopaedic surgeons predict who will benefit from surgery when patients present with degenerative meniscal tears? A survey of 194 orthopaedic surgeons who made 3880 predictions
Bloembergen, Coen H. , Graaf, Victor A. van de , Virgile, Adam , Noorduyn, Julia C. A. , Saris, Daniël B.F. , Poolman, Rudolf W. , van de Graaf, Victor A , Saris, Daniel Bf, Willigenburg, Nienke Willemien , Harris, Ian Andrew

Mayo Clinic

British Journal of Sports Medicine | October 25, 2019 | Volume: 54 | Issue: 9 | Pages: 556-557

10.1136/bjsports-2019-101502 | PMID 31653776 Get It

Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients
Roelsgaard, Ida Kristiane , Ikdahl, Eirik , Rollefstad, Silvia , Wibetoe, Grunde , Riel, Piet L. C. M. van , Gabriel, Sherine E., Douglas, Karen, Wållberg‐Jonsson, Solveig , Dessein, Patrick H , Tsang, Linda , Hitchon, Carol , Pascual‐Ramos, Virginia , Contreras-Yáñez, Irazú , Sfikakis, Petros P. , González‐Gay, Miguel Á. , Crowson, Cynthia S. , Gabriel, Sherine, Gonzalez-Gay, Miguel A , Esbensen, Bente Appel , Kitas, George D. , Kvien, Tore Kristian , Rantapää‐Dahlqvist, Solbritt , Karpouzas, George , El‐Gabalawy, Hani , Semb, Anne Grete

Mayo Clinic

Rheumatology | October 25, 2019 | Volume: 59 | Issue: 8 | Pages: 1997-2004

10.1093/rheumatology/kez557 | PMID 31782789 Get It

Abstract Objectives Smoking is a major risk factor for the development of both cardiovascular disease (CVD) and RA and may cause attenuated responses to anti-rheumatic treatments. Our aim was to compare disease activity, CVD risk factors and CVD event rates across smoking status in RA patients. Methods Disease characteristics, CVD risk factors and relevant medications were recorded in RA patients without prior CVD from 10 countries (Norway, UK, Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico). Information on CVD events was collected. Adjusted analysis of variance, logistic regression and Cox models were applied to compare RA disease activity (DAS28), CVD risk factors and event rates across categories of smoking status. Results Of the 3311 RA patients (1012 former, 887 current and 1412 never smokers), 235 experienced CVD events during a median follow-up of 3.5 years (interquartile range 2.5–6.1). At enrolment, current smokers were more likely to have moderate or high disease activity compared with former and never smokers (P < 0.001 for both). There was a gradient of worsening CVD risk factor profiles (lipoproteins and blood pressure) from never to former to current smokers. Furthermore, former and never smokers had significantly lower CVD event rates compared with current smokers [hazard ratio 0.70 (95% CI 0.51, 0.95), P = 0.02 and 0.48 (0.34, 0.69), P < 0.001, respectively]. The CVD event rates for former and never smokers were comparable. Conclusion Smoking cessation in patients with RA was associated with lower disease activity and improved lipid profiles and was a predictor of reduced rates of CVD events.
Outcomes and Complications in the Management of Distal Radial Fractures in the Elderly
DeGeorge, Brent R. , Houten, Holly K. Van , Mwangi, Raphael , Sangaralingham, Lindsey R. , Larson, A. Noelle , Kakar, Sanjeev , Van Houten, Holly K , Larson, A Noelle , Kakar, Sanjeev

Mayo Clinic

Journal of Bone and Joint Surgery | October 25, 2019 | Volume: 102 | Issue: 1 | Pages: 37-44

10.2106/jbjs.18.00561 | PMID 31651702 Get It

Background: The purpose of the present study was to identify trends in management and to compare the outcomes and complications following nonoperative and operative management (including external fixation, closed reduction and percutaneous pinning, and open reduction and internal fixation) for distal radial fractures in patients ≥65 years of age. Methods: We performed a retrospective analysis, with use of the OptumLabs Data Warehouse database, of patients ≥65 years of age who had been managed for a distal radial fracture between 2009 and 2014 (as indicated by diagnosis codes according to the International Classification of Diseases, Ninth Revision, Clinical Modification). Ninety-day and 1-year complication rates per 1,000 fractures were analyzed overall and by treatment modality. Results: Thirteen thousand, seven hundred and thirteen distal radial fractures were analyzed. The overall 90-day complication rate was 36.5 per 1,000 fractures, and the 1-year upper-extremity-specific complication rate was 236.2 and 307.5 per 1,000 fractures for nonoperative and operative management, respectively. Overall, post-injury stiffness was the most common 1-year upper-extremity-specific complication (incidence, 11.5%). There was no significant difference between operative and nonoperative management in terms of 90-day complication rates. However, operative management had a higher 1-year complication rate than nonoperative management (307.5 versus 236.2 per 1,000 fractures). Overall, the 5 most common upper-extremity-specific complications following operative treatment of distal radial fracture were stiffness (16.0%), chronic regional pain syndrome (9.9%), median neuropathy (8.0%), implant-related complications (3.8%), and tendon-related complications (2.8%). Stiffness was significantly more frequent following operative management (16.0% versus 9.8%; p < 0.01). Conclusions: Operative management of a distal radial fracture should be carefully considered when discussing treatment options with patients ≥65 years of age. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Knockdown of formin mDia2 alters lamin B1 levels and increases osteogenesis in stem cells
Sankaran, Jeyantt Srinivas , Sen, Buer , Dudakovic, Amel , Paradise, Christopher R. , Perdue, Tony D., McGrath, Cody , Styner, Maya , Newberg, Joshua, Uzer, Gunes , Wijnen, André J. van , Rubin, Janet , Sankaran, Jeyantt S , van Wijnen, Andre J , Rubin, Janet , van Wijnen, Andre J , Styner, Maya , Xie, Zhihui

Mayo Clinic

Stem Cells | October 24, 2019 | Volume: 38 | Issue: 1 | Pages: 102-117

10.1002/stem.3098 | PMID 31648392 Get It

AbstractNuclear actin plays a critical role in mediating mesenchymal stem cell (MSC) fate commitment. In marrow-derived MSCs, the principal diaphanous-related formin Diaph3 (mDia2) is present in the nucleus and regulates intranuclear actin polymerization, whereas Diaph1 (mDia1) is localized to the cytoplasm and controls cytoplasmic actin polymerization. We here show that mDia2 can be used as a tool to query actin-lamin nucleoskeletal structure. Silencing mDia2 affected the nucleoskeletal lamin scaffold, altering nuclear morphology without affecting cytoplasmic actin cytoskeleton, and promoted MSC differentiation. Attempting to target intranuclear actin polymerization by silencing mDia2 led to a profound loss in lamin B1 nuclear envelope structure and integrity, increased nuclear height, and reduced nuclear stiffness without compensatory changes in other actin nucleation factors. Loss of mDia2 with the associated loss in lamin B1 promoted Runx2 transcription and robust osteogenic differentiation and suppressed adipogenic differentiation. Hence, mDia2 is a potent tool to query intranuclear actin-lamin nucleoskeletal structure, and its presence serves to retain multipotent stromal cells in an undifferentiated state.
Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project
Visser, Leonie N.C. , Pelt, Sophie, Kunneman, Marleen , Claus, Jules J. , Kalisvaart, Kees J. , Hempenius, Liesbeth, Beer, Marlijn H. de, Roks, Gerwin , Boelaarts, Leo, Kleijer, Mariska, Smets, Ellen M.A. , Hillen, Marij A. , Bouwman, Femke H. , Flier, Wiesje M. van der

Mayo Clinic

Health Expectations | October 22, 2019 | Volume: 23 | Issue: 1 | Pages: 52-62

10.1111/hex.12964 | PMID 31638322 Get It

AbstractBackgroundThe development of novel diagnostics enables increasingly earlier diagnosis of Alzheimer's disease (AD). Timely diagnosis may benefit patients by reducing their uncertainty regarding the cause of symptoms, yet does not always provide patients with the desired certainty.ObjectiveTo examine, using both quantitative and qualitative methods, uncertainty communicated by memory clinic clinicians in post‐diagnostic testing consultations with patients and their caregivers.MethodsFirst, we identified all uncertainty expressions of 22 clinicians in audiotaped post‐diagnostic testing consultations with 78 patients. Second, we statistically explored relationships between patient/clinician characteristics and uncertainty expressions. Third, the transcribed uncertainty expressions were qualitatively analysed, determining the topic to which they pertained, their source and initiator/elicitor (clinicians/patients/caregivers).ResultsWithin 57/78 (73%) consultations, clinicians expressed in total 115 uncertainties, of which 37% elicited by the patient or caregiver. No apparent relationships were found between patient/clinician characteristics and whether or not, and how often clinicians expressed uncertainty. Uncertainty expressions pertained to ten different topics, most frequently patient's diagnosis and symptom progression. Expressed uncertainty was mostly related to the unpredictability of the future and limits to available knowledge.Discussion and conclusionsThe majority of clinicians openly discussed the limits of scientific knowledge and diagnostic testing with patients and caregivers in the dementia context. Noticeably, clinicians did not discuss uncertainty in about one quarter of consultations. More evidence is needed on the beneficial and/or harmful effects on patients of discussing uncertainty with them. This knowledge can be used to support clinicians to optimally convey uncertainty and facilitate patients' uncertainty management.
3076Individual patient meta-analysis of global longitudinal strain: is one normal range enough?
D’Elia, Nicholas , Kosmala, Wojciech , Lancellotti, Patrizio , Grootel, Roderick W. J. van , Villarraga, Hector R. , Caselli, Stefano , Bosch, Annemien Elise van den , Morris, Daniel Armando , Muraru, Denisa , Takeuchi, Masaaki , Marwick, Thomas H.

Mayo Clinic

European Heart Journal | October 21, 2019 | Volume: 40 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehz745.0032 Get It

Abstract Background Despite over a decade of evidence, uptake of GLS into guidelines and practice has been slow. Age, BP, and software have been reported to influence GLS, and have led to uncertainty about defining the normal range (NR). As there have been software changes since the last meta-analysis, we sought to define NR in the current era. Methods Pubmed, Cochrane, and EMBASE were searched using the keywords “Left Ventricle”, “Normal global longitudinal strain”, and “Speckle tracking Echocardiography” and relevant synonyms from 2011. Studies were included if they reported GLS based on speckle tracking techniques, included at least 20 healthy individuals, and had up to date contact details available. Healthy was defined as lack of known disease. Platforms used included General Electric, Philips, Canon and Tomtec. The authors of 8 of the 12 studies (67% response) provided individual patient data. Linear regression was used to determine predictors of GLS. Results There were 2396 pts, mean age 42 years (range 18–92), weight 66±12kg, height 169±9cm, BSA 1.7±0.2m2, and SBP 120±13 mmHg. Normal range for GLS was 21.0±2.6%. In multivariable analysis age (β=-0.02, p<0.01), weight (β=-0.03, p<0.01), SBP (β=-0.01, p<0.01) and platform were associated with GLS. GLS tends to vary with extremes of age and BP (see Figure 1 and Figure 2). GLS vs Age group Conclusion Extremes of age and BP may lead to low GLS, but generally, GLS is <16% is abnormal. Acknowledgement/Funding None
Radiological and clinical predictors of scoliosis in patients with Chiari malformation type I and spinal cord syrinx from the Park-Reeves Syringomyelia Research Consortium
Strahle, Jennifer M. , Taiwo, Rukayat , Averill, Christine, Torner, James C., Shannon, Chevis N. , Bonfield, Christopher M. , Tuite, Gerald F. , Bethel-Anderson, Tammy, Rutlin, Jerrel, Brockmeyer, Douglas L. , Wellons, John C. , Leonard, Jeffrey R. , Mangano, Francesco T. , Johnston, James M. , Iskandar, Bermans J. , Tyler‐Kabara, Elizabeth C. , Jackson, Eric M. , Couture, Daniel E., Adelson, P. David , Alden, Tord D. , Aldana, Philipp R. , Anderson, Richard C. E. , Baird, Lissa , Bierbrauer, Karin S. , Chern, Joshua J. , Whitehead, William E. , Ellenbogen, Richard G. , Fuchs, Herbert E., Guillaume, Daniel, Hankinson, Todd C. , Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Khan, Nickalus R. , Muhlbauer, Michael S., McComb, J. Gordon , Menezes, Arnold H. , Ragheb, John , Smith, Jodi L. , Maher, Cormac O. , Greene, Stephanie , Kelly, Michael P. , O’Neill, Brent R., Krieger, Mark D., Tamber, Mandeep S. , Durham, Susan, Olavarria, Greg, Stone, Scellig , Kaufman, Bruce A., Heuer, Gregory G. , Bauer, David F. , Albert, Gregory W. , Greenfield, Jeffrey P. , Wait, Scott D. , Poppel, Mark D Van, Eskandari, Ramin , Mapstone, Timothy B., Dacey, Ralph G. , Park, Tae Sung, Limbrick, David D. , Torner, James C. , Kelly, Michael P , Shah, Manish N. , Daniels, David J. , Grant, Gerald A. , Selden, Nathan R. W. , Guillaume, Daniel J., Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 19, 2019 | Volume: 24 | Issue: 5 | Pages: 520-527

10.3171/2019.5.peds18527 | PMID 31419800 Get It

OBJECTIVEScoliosis is frequently a presenting sign of Chiari malformation type I (CM-I) with syrinx. The authors’ goal was to define scoliosis in this population and describe how radiological characteristics of CM-I and syrinx relate to the presence and severity of scoliosis.METHODSA large multicenter retrospective and prospective registry of pediatric patients with CM-I (tonsils ≥ 5 mm below the foramen magnum) and syrinx (≥ 3 mm in axial width) was reviewed for clinical and radiological characteristics of CM-I, syrinx, and scoliosis (coronal curve ≥ 10°).RESULTSBased on available imaging of patients with CM-I and syrinx, 260 of 825 patients (31%) had a clear diagnosis of scoliosis based on radiographs or coronal MRI. Forty-nine patients (5.9%) did not have scoliosis, and in 516 (63%) patients, a clear determination of the presence or absence of scoliosis could not be made. Comparison of patients with and those without a definite scoliosis diagnosis indicated that scoliosis was associated with wider syrinxes (8.7 vs 6.3 mm, OR 1.25, p < 0.001), longer syrinxes (10.3 vs 6.2 levels, OR 1.18, p < 0.001), syrinxes with their rostral extent located in the cervical spine (94% vs 80%, OR 3.91, p = 0.001), and holocord syrinxes (50% vs 16%, OR 5.61, p < 0.001). Multivariable regression analysis revealed syrinx length and the presence of holocord syrinx to be independent predictors of scoliosis in this patient cohort. Scoliosis was not associated with sex, age at CM-I diagnosis, tonsil position, pB–C2 distance (measured perpendicular distance from the ventral dura to a line drawn from the basion to the posterior-inferior aspect of C2), clivoaxial angle, or frontal-occipital horn ratio. Average curve magnitude was 29.9°, and 37.7% of patients had a left thoracic curve. Older age at CM-I or syrinx diagnosis (p < 0.0001) was associated with greater curve magnitude whereas there was no association between syrinx dimensions and curve magnitude.CONCLUSIONSSyrinx characteristics, but not tonsil position, were related to the presence of scoliosis in patients with CM-I, and there was an independent association of syrinx length and holocord syrinx with scoliosis. Further study is needed to evaluate the nature of the relationship between syrinx and scoliosis in patients with CM-I.
P4‐537: DETECTION OF ALZHEIMER'S DISEASE IN CSF USING AUTOMATED ASSAYS FOR CLASSICAL CSF BIOMARKERS
Wiste, Heather J. , Weigand, Stephen D. , Eichenlaub, Udo, Batrla‐Utermann, Richard, Dyer, Roy B. , Algeciras‐Schimnic, Alicia, Petersen, Ronald C. , Harten, Argonde C. van , Mielke, Michelle M. , Kremers, Walter K. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_29 | Pages: No page available

10.1016/j.jalz.2019.08.084 Get It

O4‐02‐01: PHASE 2A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRM‐0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS
Boxer, Adam L. , Moebius, Hans J. , Harris, Baruch, Mummery, Catherine, Ber, Isabelle Le , Hannequin, Didier , McGinnis, Scott M., Auriacombe, Sophie, Goodman, Ira , Riordan, Henry, Wisniewski, Gary, Hesterman, Jacob , Patzke, Holger, Koenig, Gerhard, Hilt, Dana, Boeve, Bradley F. , Borroni, Barbara , Swieten, John C. van , Grossman, Murray , Pasquier, Florence , Frisoni, Giovanni B. , Vandenberghe, Rik , ONOFRJ, MARCO C. , Marek, Kenneth

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_23 | Pages: No page available

10.1016/j.jalz.2019.06.4746 Get It